Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23709479 | 0.98 | BDKRB2 (0.35) | BDKRB2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL7524050 | 0.94 | DNM1 (0.34) | BDKRB2TLR8 | |
| SCHEMBL26078434 | 0.92 | LMNA (0.36) | KCNH2 | |
| SCHEMBL19134116 | 0.92 | DNM1 (0.38) | KCNH2 | |
| SCHEMBL21715637 | 0.91 | OPRM1 (0.34) | BDKRB2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL13632434 | 0.91 | KCNA5 (0.35) | CYP2D6TLR8TLR7KCNA5KCNH2 | |
| SCHEMBL21029966 | 0.89 | LMNA (0.37) | KCNH2 | |
| SCHEMBL18948470 | 0.89 | LMNA (0.37) | KCNH2 | |
| SCHEMBL24688358 | 0.89 | LMNA (0.37) | KCNH2 | |
| SCHEMBL21004269 | 0.89 | LMNA (0.37) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | BDKRB2 4547/4885CYP1A2 2523/4885CYP2D6 3649/4885 |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | HDAC6, HDAC1, HDAC3 | BDKRB2 4604/4885CYP1A2 2892/4885CYP2D6 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.